GRAL
GRAIL, Inc.
Key Financials
Revenue
$147.2M
↑ 17.2%
Operating Income
$-562163000
↑ 74.3%
Net Income
$-408351000
↑ 79.9%
EPS (Diluted)
$-11.11
↑ 82.5%
Shareholders' Equity
$2.6B
↑ 3.0%
Total Assets
$2.9B
↓ 2.1%
Total Liabilities
$344.2M
↓ 28.3%
Cash & Equivalents
$249.7M
↑ 16.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/11/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
| DEF 14A | 4/28/2026 | View on SEC |
| 4 | 4/17/2026 | View on SEC |
| 4 | 4/17/2026 | View on SEC |
| 4 | 4/17/2026 | View on SEC |
| 4 | 4/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GRAL |
| Company Name | GRAIL, Inc. |
| CIK | 1699031 |
| Sector | Services-Medical Laboratories |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (833) 694-2553 |